isoproterenol	Metoprolol	4	4	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  		6054	6918	D007545	D008790
isoproterenol	Metoprolol	4	4	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  		6054	6918	D007545	D008790
isoproterenol	Metoprolol	4	5	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  		6054	6918	D007545	D008790
isoproterenol	Metoprolol	4	5	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  		6054	6918	D007545	D008790
isoproterenol	Metoprolol	4	6	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  		6054	6918	D007545	D008790
isoproterenol	Metoprolol	4	6	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  		6054	6918	D007545	D008790
isoproterenol	metoprolol	4	4	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  		6054	6918	D007545	D008790
isoproterenol	metoprolol	4	4	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  		6054	6918	D007545	D008790
isoproterenol	metoprolol	4	5	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  		6054	6918	D007545	D008790
isoproterenol	metoprolol	4	5	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  		6054	6918	D007545	D008790
isoproterenol	metoprolol	4	6	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  		6054	6918	D007545	D008790
isoproterenol	metoprolol	4	6	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  		6054	6918	D007545	D008790
metoprolol succinate	Metoprolol	33	31	true	positive	Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  		221124	D008790
metoprolol succinate	Metoprolol	33	34	true	positive	Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations.  		221124	D008790
metoprolol succinate	Metoprolol	33	32	false	none	The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  		221124	D008790
metoprolol succinate	Metoprolol	33	33	false	none	Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  		221124	D008790
metoprolol succinate	metoprolol	33	31	true	positive	Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  		221124	D008790
metoprolol succinate	metoprolol	33	34	true	positive	Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations.  		221124	D008790
metoprolol succinate	metoprolol	33	32	false	none	The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  		221124	D008790
metoprolol succinate	metoprolol	33	33	false	none	Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  		221124	D008790
TOPROL-XL	Metoprolol	38	38	false	none	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	38	38	false	none	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	38	39	true	positive	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	38	39	true	positive	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	38	36	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	38	36	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	38	37	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	38	37	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	21	23	true	positive	TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	21	23	true	positive	TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	21	22	false	none	TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	21	22	false	none	TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	39	38	true	positive	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	39	38	true	positive	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	39	39	true	positive	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	39	39	true	positive	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	39	37	true	positive	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	39	37	true	positive	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	39	41	false	none	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  Nevertheless, over the 24-hour dosing interval, β1-blockade is comparable and dose-related [see Clinical Pharmacology (12)].  The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	39	41	false	none	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  Nevertheless, over the 24-hour dosing interval, β1-blockade is comparable and dose-related [see Clinical Pharmacology (12)].  The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	20	22	false	none	In other studies, treatment with TOPROL-XL produced an improvement in left ventricular ejection fraction.  TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	20	22	false	none	In other studies, treatment with TOPROL-XL produced an improvement in left ventricular ejection fraction.  TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	37	38	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	37	38	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	37	39	true	positive	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	37	39	true	positive	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	37	36	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	37	36	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	37	37	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	37	37	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	42	43	false	none	Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	42	43	false	none	Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	42	41	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	42	41	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	42	44	false	none	Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	42	44	false	none	Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	41	39	false	none	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  Nevertheless, over the 24-hour dosing interval, β1-blockade is comparable and dose-related [see Clinical Pharmacology (12)].  The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	41	39	false	none	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  Nevertheless, over the 24-hour dosing interval, β1-blockade is comparable and dose-related [see Clinical Pharmacology (12)].  The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	41	43	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	41	43	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	41	41	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
TOPROL-XL	Metoprolol	41	41	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	38	38	false	none	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	38	38	false	none	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	38	39	true	positive	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	38	39	true	positive	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	38	36	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	38	36	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	38	37	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	38	37	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	21	23	true	positive	TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	21	23	true	positive	TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	21	22	false	none	TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	21	22	false	none	TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	39	38	true	positive	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	39	38	true	positive	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	39	39	true	positive	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	39	39	true	positive	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	39	37	true	positive	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	39	37	true	positive	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	39	41	false	none	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  Nevertheless, over the 24-hour dosing interval, β1-blockade is comparable and dose-related [see Clinical Pharmacology (12)].  The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	39	41	false	none	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  Nevertheless, over the 24-hour dosing interval, β1-blockade is comparable and dose-related [see Clinical Pharmacology (12)].  The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	20	22	false	none	In other studies, treatment with TOPROL-XL produced an improvement in left ventricular ejection fraction.  TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	20	22	false	none	In other studies, treatment with TOPROL-XL produced an improvement in left ventricular ejection fraction.  TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.  12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	37	38	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	37	38	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	37	39	true	positive	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	37	39	true	positive	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	37	36	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	37	36	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	37	37	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	37	37	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	42	43	false	none	Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	42	43	false	none	Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	42	41	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	42	41	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	42	44	false	none	Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	42	44	false	none	Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	41	39	false	none	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  Nevertheless, over the 24-hour dosing interval, β1-blockade is comparable and dose-related [see Clinical Pharmacology (12)].  The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	41	39	false	none	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  Nevertheless, over the 24-hour dosing interval, β1-blockade is comparable and dose-related [see Clinical Pharmacology (12)].  The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	41	43	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	41	43	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	41	41	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
TOPROL-XL	metoprolol	41	41	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		0	6918	C402833	D008790
epinephrine	Metoprolol	9	7	false	none	Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	9	7	false	none	Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	9	8	false	none	Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	9	8	false	none	Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	9	9	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	9	9	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	9	11	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	9	11	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	10	8	false	none	Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	10	8	false	none	Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	10	9	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	10	9	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	10	11	false	none	This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	10	11	false	none	This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	10	12	false	none	This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  		3992	6918	D004837	D008790
epinephrine	Metoprolol	10	12	false	none	This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  		3992	6918	D004837	D008790
epinephrine	metoprolol	9	7	false	none	Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	metoprolol	9	7	false	none	Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	metoprolol	9	8	false	none	Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	metoprolol	9	8	false	none	Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	metoprolol	9	9	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	metoprolol	9	9	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	metoprolol	9	11	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	6918	D004837	D008790
epinephrine	metoprolol	9	11	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	6918	D004837	D008790
epinephrine	metoprolol	10	8	false	none	Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	metoprolol	10	8	false	none	Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	metoprolol	10	9	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	metoprolol	10	9	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  		3992	6918	D004837	D008790
epinephrine	metoprolol	10	11	false	none	This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	6918	D004837	D008790
epinephrine	metoprolol	10	11	false	none	This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	6918	D004837	D008790
epinephrine	metoprolol	10	12	false	none	This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  		3992	6918	D004837	D008790
epinephrine	metoprolol	10	12	false	none	This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  		3992	6918	D004837	D008790
epinephrine	propranolol	9	11	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	8787	D004837	D011433
epinephrine	propranolol	9	11	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	8787	D004837	D011433
epinephrine	propranolol	10	11	false	none	This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	8787	D004837	D011433
epinephrine	propranolol	10	11	false	none	This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		3992	8787	D004837	D011433
Metoprolol	metoprolol	4	4	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  		D008790	D008790
Metoprolol	metoprolol	4	5	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  		D008790	D008790
Metoprolol	metoprolol	4	6	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  		D008790	D008790
Metoprolol	metoprolol	5	4	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  		D008790	D008790
Metoprolol	metoprolol	5	5	false	none	Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  		D008790	D008790
Metoprolol	metoprolol	5	6	false	none	Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  		D008790	D008790
Metoprolol	metoprolol	5	7	false	none	Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  		D008790	D008790
Metoprolol	metoprolol	6	4	false	none	12.2 Pharmacodynamics    Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.  Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  		D008790	D008790
Metoprolol	metoprolol	6	5	false	none	Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  		D008790	D008790
Metoprolol	metoprolol	6	6	false	none	This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  		D008790	D008790
Metoprolol	metoprolol	6	7	false	none	This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  		D008790	D008790
Metoprolol	metoprolol	6	8	false	none	This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  		D008790	D008790
Metoprolol	metoprolol	7	5	false	none	Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent.  This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  		D008790	D008790
Metoprolol	metoprolol	7	6	false	none	This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  		D008790	D008790
Metoprolol	metoprolol	7	7	false	none	Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  		D008790	D008790
Metoprolol	metoprolol	7	8	false	none	Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  		D008790	D008790
Metoprolol	metoprolol	7	9	false	none	Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		D008790	D008790
Metoprolol	metoprolol	8	6	false	none	This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2-adrenoreceptors, chiefly located in the bronchial and vascular musculature.  Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  		D008790	D008790
Metoprolol	metoprolol	8	7	false	none	Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  		D008790	D008790
Metoprolol	metoprolol	8	8	false	none	Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  		D008790	D008790
Metoprolol	metoprolol	8	9	false	none	Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		D008790	D008790
Metoprolol	metoprolol	9	7	false	none	Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.  Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		D008790	D008790
Metoprolol	metoprolol	9	8	false	none	Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.  The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		D008790	D008790
Metoprolol	metoprolol	9	9	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  		D008790	D008790
Metoprolol	metoprolol	9	11	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		D008790	D008790
Metoprolol	metoprolol	11	9	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		D008790	D008790
Metoprolol	metoprolol	11	11	false	none	(2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		D008790	D008790
Metoprolol	metoprolol	11	12	false	none	(2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  		D008790	D008790
Metoprolol	metoprolol	12	11	false	none	(2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  		D008790	D008790
Metoprolol	metoprolol	12	12	true	positive	The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  		D008790	D008790
Metoprolol	metoprolol	12	14	true	positive	The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  Using an Emax model, the maximum effect is a 30% reduction in exercise heart rate, which is attributed to beta1-blockade.  Beta1-blocking effects in the range of 30-80% of the maximal effect (approximately 8-23% reduction in exercise heart rate) correspond to metoprolol plasma concentrations from 30-540 nmol/L.  		D008790	D008790
Metoprolol	metoprolol	14	12	true	positive	The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  Using an Emax model, the maximum effect is a 30% reduction in exercise heart rate, which is attributed to beta1-blockade.  Beta1-blocking effects in the range of 30-80% of the maximal effect (approximately 8-23% reduction in exercise heart rate) correspond to metoprolol plasma concentrations from 30-540 nmol/L.  		D008790	D008790
Metoprolol	metoprolol	14	14	false	none	Beta1-blocking effects in the range of 30-80% of the maximal effect (approximately 8-23% reduction in exercise heart rate) correspond to metoprolol plasma concentrations from 30-540 nmol/L.  		D008790	D008790
Metoprolol	metoprolol	14	15	false	none	Beta1-blocking effects in the range of 30-80% of the maximal effect (approximately 8-23% reduction in exercise heart rate) correspond to metoprolol plasma concentrations from 30-540 nmol/L.  The relative beta1-selectivity of metoprolol diminishes and blockade of beta2-adrenoceptors increases at plasma concentration above 300 nmol/L.  		D008790	D008790
Metoprolol	metoprolol	15	14	false	none	Beta1-blocking effects in the range of 30-80% of the maximal effect (approximately 8-23% reduction in exercise heart rate) correspond to metoprolol plasma concentrations from 30-540 nmol/L.  The relative beta1-selectivity of metoprolol diminishes and blockade of beta2-adrenoceptors increases at plasma concentration above 300 nmol/L.  		D008790	D008790
Metoprolol	metoprolol	15	15	true	positive	The relative beta1-selectivity of metoprolol diminishes and blockade of beta2-adrenoceptors increases at plasma concentration above 300 nmol/L.  		D008790	D008790
Metoprolol	metoprolol	23	23	true	positive	Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.  		D008790	D008790
Metoprolol	metoprolol	23	22	true	positive	12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.  		D008790	D008790
Metoprolol	metoprolol	23	24	true	positive	Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.  Metoprolol crosses the blood-brain barrier and has been reported in the CSF in a concentration 78% of the simultaneous plasma concentration.  		D008790	D008790
Metoprolol	metoprolol	22	23	true	positive	12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.  		D008790	D008790
Metoprolol	metoprolol	22	22	false	none	12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  		D008790	D008790
Metoprolol	metoprolol	22	24	true	positive	12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.  Metoprolol crosses the blood-brain barrier and has been reported in the CSF in a concentration 78% of the simultaneous plasma concentration.  		D008790	D008790
Metoprolol	metoprolol	24	23	true	positive	Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.  Metoprolol crosses the blood-brain barrier and has been reported in the CSF in a concentration 78% of the simultaneous plasma concentration.  		D008790	D008790
Metoprolol	metoprolol	24	22	true	positive	12.3 Pharmacokinetics    Adults: In man, absorption of metoprolol is rapid and complete.  Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.  Metoprolol crosses the blood-brain barrier and has been reported in the CSF in a concentration 78% of the simultaneous plasma concentration.  		D008790	D008790
Metoprolol	metoprolol	24	24	false	none	Metoprolol crosses the blood-brain barrier and has been reported in the CSF in a concentration 78% of the simultaneous plasma concentration.  		D008790	D008790
Metoprolol	metoprolol	27	27	false	none	Metoprolol is a racemic mixture of R- and S- enantiomers, and is primarily metabolized by CYP2D6.  		D008790	D008790
Metoprolol	metoprolol	31	31	true	positive	Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  		D008790	D008790
Metoprolol	metoprolol	31	30	true	positive	Less than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.  Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  		D008790	D008790
Metoprolol	metoprolol	31	32	true	positive	Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  		D008790	D008790
Metoprolol	metoprolol	31	33	true	positive	Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  		D008790	D008790
Metoprolol	metoprolol	30	31	true	positive	Less than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.  Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  		D008790	D008790
Metoprolol	metoprolol	30	30	false	none	Less than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.  		D008790	D008790
Metoprolol	metoprolol	30	32	true	positive	Less than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.  Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  		D008790	D008790
Metoprolol	metoprolol	34	34	false	none	Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations.  		D008790	D008790
Metoprolol	metoprolol	34	32	false	none	The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations.  		D008790	D008790
Metoprolol	metoprolol	34	33	true	positive	Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations.  		D008790	D008790
Metoprolol	metoprolol	34	36	false	none	Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations.  CYP2D6 can be inhibited by a number of drugs.  Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  		D008790	D008790
Metoprolol	metoprolol	32	31	true	positive	Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  		D008790	D008790
Metoprolol	metoprolol	32	30	true	positive	Less than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.  Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  		D008790	D008790
Metoprolol	metoprolol	32	34	false	none	The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations.  		D008790	D008790
Metoprolol	metoprolol	32	32	false	none	The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  		D008790	D008790
Metoprolol	metoprolol	32	33	false	none	The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  		D008790	D008790
Metoprolol	metoprolol	33	31	true	positive	Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  		D008790	D008790
Metoprolol	metoprolol	33	34	true	positive	Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations.  		D008790	D008790
Metoprolol	metoprolol	33	32	false	none	The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  		D008790	D008790
Metoprolol	metoprolol	33	33	false	none	Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.  		D008790	D008790
Metoprolol	metoprolol	38	38	false	none	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		D008790	D008790
Metoprolol	metoprolol	38	39	true	positive	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		D008790	D008790
Metoprolol	metoprolol	38	36	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		D008790	D008790
Metoprolol	metoprolol	38	37	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		D008790	D008790
Metoprolol	metoprolol	39	38	true	positive	The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		D008790	D008790
Metoprolol	metoprolol	39	39	true	positive	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		D008790	D008790
Metoprolol	metoprolol	39	37	true	positive	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		D008790	D008790
Metoprolol	metoprolol	39	41	false	none	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  Nevertheless, over the 24-hour dosing interval, β1-blockade is comparable and dose-related [see Clinical Pharmacology (12)].  The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		D008790	D008790
Metoprolol	metoprolol	36	34	false	none	Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations.  CYP2D6 can be inhibited by a number of drugs.  Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  		D008790	D008790
Metoprolol	metoprolol	36	38	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		D008790	D008790
Metoprolol	metoprolol	36	36	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  		D008790	D008790
Metoprolol	metoprolol	36	37	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  		D008790	D008790
Metoprolol	metoprolol	37	38	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  		D008790	D008790
Metoprolol	metoprolol	37	39	true	positive	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses.  At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  		D008790	D008790
Metoprolol	metoprolol	37	36	false	none	Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].  In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  		D008790	D008790
Metoprolol	metoprolol	37	37	false	none	In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation.  		D008790	D008790
Metoprolol	metoprolol	43	43	false	none	The pharmacokinetics of metoprolol were similar to those described previously in adults.  		D008790	D008790
Metoprolol	metoprolol	43	41	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  		D008790	D008790
Metoprolol	metoprolol	43	44	false	none	The pharmacokinetics of metoprolol were similar to those described previously in adults.  Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  		D008790	D008790
Metoprolol	metoprolol	43	45	false	none	The pharmacokinetics of metoprolol were similar to those described previously in adults.  Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  Metoprolol apparent oral clearance (CL/F) increased linearly with body weight.  		D008790	D008790
Metoprolol	metoprolol	41	39	false	none	At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol.  Nevertheless, over the 24-hour dosing interval, β1-blockade is comparable and dose-related [see Clinical Pharmacology (12)].  The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		D008790	D008790
Metoprolol	metoprolol	41	43	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily.  The pharmacokinetics of metoprolol were similar to those described previously in adults.  		D008790	D008790
Metoprolol	metoprolol	41	41	false	none	The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.  		D008790	D008790
Metoprolol	metoprolol	46	46	true	positive	Metoprolol pharmacokinetics have not been investigated in patients < 6 years of age.  		D008790	D008790
Metoprolol	metoprolol	46	44	true	negative	Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  Metoprolol apparent oral clearance (CL/F) increased linearly with body weight.  Metoprolol pharmacokinetics have not been investigated in patients < 6 years of age.  		D008790	D008790
Metoprolol	metoprolol	46	45	true	positive	Metoprolol apparent oral clearance (CL/F) increased linearly with body weight.  Metoprolol pharmacokinetics have not been investigated in patients < 6 years of age.  		D008790	D008790
Metoprolol	metoprolol	44	43	false	none	The pharmacokinetics of metoprolol were similar to those described previously in adults.  Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  		D008790	D008790
Metoprolol	metoprolol	44	46	true	negative	Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  Metoprolol apparent oral clearance (CL/F) increased linearly with body weight.  Metoprolol pharmacokinetics have not been investigated in patients < 6 years of age.  		D008790	D008790
Metoprolol	metoprolol	44	44	false	none	Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  		D008790	D008790
Metoprolol	metoprolol	44	45	false	none	Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  Metoprolol apparent oral clearance (CL/F) increased linearly with body weight.  		D008790	D008790
Metoprolol	metoprolol	45	43	false	none	The pharmacokinetics of metoprolol were similar to those described previously in adults.  Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  Metoprolol apparent oral clearance (CL/F) increased linearly with body weight.  		D008790	D008790
Metoprolol	metoprolol	45	46	true	positive	Metoprolol apparent oral clearance (CL/F) increased linearly with body weight.  Metoprolol pharmacokinetics have not been investigated in patients < 6 years of age.  		D008790	D008790
Metoprolol	metoprolol	45	44	false	none	Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics.  Metoprolol apparent oral clearance (CL/F) increased linearly with body weight.  		D008790	D008790
Metoprolol	metoprolol	45	45	false	none	Metoprolol apparent oral clearance (CL/F) increased linearly with body weight.  		D008790	D008790
Metoprolol	propranolol	9	11	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		6918	8787	D008790	D011433
Metoprolol	propranolol	9	11	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		6918	8787	D008790	D011433
Metoprolol	propranolol	11	11	false	none	(2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		6918	8787	D008790	D011433
Metoprolol	propranolol	11	11	false	none	(2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		6918	8787	D008790	D011433
Metoprolol	propranolol	12	11	false	none	(2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  		6918	8787	D008790	D011433
Metoprolol	propranolol	12	11	false	none	(2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  		6918	8787	D008790	D011433
metoprolol	propranolol	9	11	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		6918	8787	D008790	D011433
metoprolol	propranolol	9	11	false	none	The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine.  This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.  (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		6918	8787	D008790	D011433
metoprolol	propranolol	11	11	false	none	(2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		6918	8787	D008790	D011433
metoprolol	propranolol	11	11	false	none	(2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  		6918	8787	D008790	D011433
metoprolol	propranolol	12	11	false	none	(2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  		6918	8787	D008790	D011433
metoprolol	propranolol	12	11	false	none	(2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.  The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.  		6918	8787	D008790	D011433
